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Introduction
Bayesian hierarchical models with random effects are
one of the most widely used methods in modern disease
mapping, as a superior alternative to standardized ratios.
These models are traditionally fitted through Markov
Chain Monte Carlo sampling (MCMC). Due to the nat-
ure of the hierarchical models and random effects, the
convergence of MCMC is very slow and unpredictable.
Recently, Integrated Nested Laplace Approximation was
developed as an alternative method to fit Bayesian hier-
archical models of the latent Gaussian class.
Materials and methods
In order to compare MCMC and INLA for disease map-
ping in terms of accuracy and computational burden, we
selected the Bayesian hierarchical model with conditional
autoregressive priors. Belgian cancer mortality data on
breast cancer and acute childhood leukaemia from 2003
until 2010 and a simulation study are used to compare
both methods. Disease counts were simulated for each
Belgian municipality based on its respective population,
and three simulation parameters: the base risk of the dis-
ease and a non-spatial and a spatial component of the rela-
tive risk. Each simulation parameter has three different
settings, leading to 27 different simulation scenarios, and
each scenario was simulated 10.000 times.
Results
The simulation study clearly shows that INLA is equiva-
lent to MCMC for parameter estimation in disease map-
ping studies. Only when the disease is statistically very
rare does INLA provide worse estimates and credible
intervals. We also see that when the spatial component
is higher, the estimates and credible intervals of both
methods become worse. The overall computational bur-
den of INLA was 42 times lower. MCMC and INLA
performed similarly for actual cancer mortality data.
Discussion
Both the simulation study and the breast cancer case
study show that INLA is a suitable alternative to MCMC
for disease mapping. Great care should be given when
the disease is statistically rare.
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